UroGen Pharma (URGN) Non Operating Income (2018 - 2023)
UroGen Pharma (URGN) posted quarterly Non Operating Income of $71000.0 for Q3 2023, up 91.89% year-on-year from $37000.0 in Q3 2022, and up 336.67% on a QoQ basis from -$30000.0 in Q2 2023.
UroGen Pharma (URGN) Non Operating Income (2018 - 2023) Analysis & Trends
UroGen Pharma (URGN) has reported Non Operating Income for 5 consecutive years, with $71000.0 the latest figure, recorded in Q3 2023.
- Quarterly Non Operating Income rose 91.89% year-over-year to $71000.0 in Q3 2023, while the trailing twelve-month figure through Sep 2023 was -$37000.0 (down 163.79% YoY) and the FY2022 annual result came in at $72000.0, up 147.06% from the prior year.
- Non Operating Income grew to $71000.0 in Q3 2023 per URGN's latest filing, from -$30000.0 in the prior quarter.
- Over the last five years, Non Operating Income for URGN reached as high as $989000.0 in Q1 2019 and fell as low as -$239000.0 in Q2 2021.
- A 4-year average of $77833.3 and a median of -$9500.0 in 2022 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income surged 331.25% — and 2023, when it plunged 275.0%.
- Year by year, Non Operating Income stood at $989000.0 in 2019, then sank by 107.79% to -$77000.0 in 2021, then gained by 18.18% to -$63000.0 in 2022, then soared by 212.7% to $71000.0 in 2023.
- According to Business Quant data, Non Operating Income over the past three periods registered $71000.0, -$30000.0, and -$15000.0 for Q3 2023, Q2 2023, and Q1 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | UroGen Pharma | 2.13 Bn | 1.99 Bn | 46.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 71,000.00 |
| Jun 30, 2023 | -30,000.00 |
| Mar 31, 2023 | -15,000.00 |
| Dec 31, 2022 | -63,000.00 |
| Sep 30, 2022 | 37,000.00 |
| Jun 30, 2022 | 102,000.00 |
| Mar 31, 2022 | -4,000.00 |
| Dec 31, 2021 | -77,000.00 |
| Sep 30, 2021 | -16,000.00 |
| Jun 30, 2021 | -239,000.00 |
| Mar 31, 2021 | 179,000.00 |
| Mar 31, 2019 | 989,000.00 |
| Mar 31, 2018 | 258,000.00 |